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To the Editor:
Ending the global tuberculosis (TB) epidemic by the year 2035 is one of the most ambitious goals of the
World Health Organization (WHO). The WHO strategy is based on three major pillars: improving TB
prevention and care, supporting bold policies, and enhancing research and innovation [1]. A better
understanding of TB epidemiology, enhanced retention in care and employment of standardised regimens
are mandatory to get closer to TB eradication both in low- and high-prevalence countries [2–5].
Mathematical modelling can be a useful tool to understand epidemiology and control of TB in
low-prevalence countries, thus leading to better approaches in terms of public health interventions [6]. In
this tough challenge for clinicians, the key actions are early diagnosis of TB patients with symptoms or
signs suggestive for TB within migratory flux through a nation, and tracking of these patients as well as
dealing with increased TB presentation in iatrogenically immunocompromised patients [7, 8]. Low-cost
interventions aimed at improving patient-contacts recording, containing outbreaks, and enhancing
adherence to diagnostic work-up and follow-up are welcome to better manage the disease burden [9].
Furthermore, a dramatic improvement in diagnostic paths and therapeutic approaches is needed nationally
and globally to reach the WHO endpoint [10]. Therefore, healthcare providers who take daily care of TB
patients require proper tools to access comprehensive data, for managing patients during follow-up, and
for data collection and analysis in multicentre observational clinical trials (MCTs) [11].
The TB Genova Network platform (www.tbnetwork.it) was developed in 2016 and it is currently online. It
allows recording of TB patients’ data and tracking of their transfer to other hospitals or outpatient services
within the network. To date, the two adult infectious disease departments of the metropolitan area of
Genoa, Italy, (Policlinico San Martino and Ospedali Galliera) are implementing the platform, while other
services (e.g. the Pneumology Dept and the Outpatient Service for Immigrants) have committed to join
the network. Patients’ administrative data are saved anonymously through a secure HTTP protocol that
assures a secure data transfer on the Internet. Personal information such as date of birth, sex, nationality,
number of cohabitants (adults and children), risk factors for TB (e.g. smoking, drinking, diabetes, HIV
and exposure to silica) can be recorded. A postal code can be added to facilitate mapping. After registering
personal information, clinical data such as patients’ symptomatology on admission, anthropometric
information, comorbidities and TB localisation can be stored. Laboratory tests performed during the
hospital stay and follow-up can be automatically loaded onto the platform. Simple diagrams make it easy
to follow weight changes, and liver and renal function parameters, thus facilitating early side-effect
identification and trend monitoring (figure 1). Imaging results can be uploaded on the platform as well,
thus becoming quickly available for comparison or online advices. For those patients who are HIV–TB
co-infected, specific information about the HIV immune–virological status, treatment, etc., can be
automatically loaded from the already-running online Ligurian HIV Network, a similar regional online
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platform [12]. Microbiological and molecular examinations can be registered and successfully tracked for
each patient. Data on the anti-TB regimen are also collected, with initial and final date of drug
administration, number of missing doses, and motivation for treatment switch, discontinuation or
termination (figure 2). Links to major drug interaction checker websites are easily available on the
platform to help avoid possible drug–drug interactions. Follow-up can be periodically reported. A visual
interface supports and simplifies the report of side-effects and weight variations. To enhance visual impact,
chromatic alerts of microbiological parameters have been added. Particularly for sputum, a red colour
highlights a positive or in progress mycobacterial culture, while a green colour highlights a negative culture
for Mycobacterium tuberculosis. All data can be both uploaded on the website or, since they are already
available on the Laboratory Information System, automatically imported from the hospitals’ databases
(table 1) [14]. The database was approved by the Comitato Etico Regionale Ligure on September 22, 2016.
In the first year of the project, 60 cases of TB (40 pulmonary and 20 extrapulmonary; 26 born in Italy and
34 foreigners) were recorded. This project represents an important effort to collect clinical, laboratory,
radiological and therapeutic data about TB patients that can be used for both clinical and research
purposes. The system minimises the risk of an incongruous duration or type of therapy for patients that
decide to change their referral clinical centre. Importantly, when a patient is taken into care by a new
centre after being lost to follow-up, all past data on their therapeutic history and any known TB resistance
are readily available, and patients do not risk a delay in proper management. Second, the intuitive
TABLE 1 Present and future functions of the TB Genova Network
Function Automatic# Notes
Present Future
Anagraphic, anthropomorphic, risk
factors and first visit data
Identity information and first visit data need to
be entered by the physician on site
HIV information •
Laboratory examinations •
Imaging •
AFB, culture, GeneXpert MTB/RIF •
GWAS •
Resistance patterns • Definition of MDR-TB and XDR-TB will be
automatically provided based on resistance
patterns
rpoB •
gyr •
kat •
rrs •
Second-line drugs •
Treatment/treatment modifications •
Follow-up •
Outcome Healthcare providers can mark a TB-episode
according to WHO definitions [13]
TB: tuberculosis; AFB: acid-fast bacillus; GWAS: genome-wide association study; MDR:
multidrug-resistant; XDR: extensively drug-resistant. #: all automatic data can be manually stored and
modified.
FIGURE 1 Example of alanine
aminotransferase (ALT) monitoring
during prolonged tuberculosis (TB)
treatment.
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interface of the platform makes it easy to use for both input and data consultation, even for untrained
users. Third, daily acquisition of laboratory results from hospital software is fully automatic and includes
visual alerts to identify microbiological results. However, other clinical information must be added
manually, with possible errors; this is mostly due to the limited diffusion of electronic medical records.
Another weakness is the absence of an automatic alarm system to inform the clinician of missed follow-up
visits, laboratory examinations or imaging studies because of the heterogeneity of follow-up programmes
that need to be tailored to a single patient. Similarly, an alert for undelivered drugs might be useful. Future
implementations might consist of regional and national distribution of the platform in order to better
understand the challenge that TB poses at both local and national levels. Currently, in the Ligurian region,
every TB case is notified through a paper document; however, other Italian regions are using online
platforms to allow faster TB surveillance. The TB Genova Network may be connected to central
surveillance systems to provide updated online surveillance data.
The TB Genova Network can support healthcare workers in administrating patients’ data within primary
care, in order to improve patients’ treatment outcomes and retention in care. Focusing on epidemiological
and clinical aspects of TB, the TB Genova Network differs from other online platforms and allows every
user to recall clinical data about the patients’ TB episodes. In addition, collected clinical information can
be used to perform observational MCTs. Although current diagnostic procedures are all included in the
network (e.g. sputum smear microscopy, sputum cultures, GeneXpert, etc.), any new diagnostic approach
for active TB diagnosis, including genome-wide association studies, may be updated and uploaded on the
TB Genova platform to improve the quality of recorded data [15]. As SOTGIU and MIGLIORI suggested [16],
better data will bring more tailored therapies for TB.
The TB Genova Network is an online tool to standardise and unify individual databases in Genoa,
preventing data waste and ensuring anonymity for patients. This network is the first Italian online cohort
of active TB and database for managing TB patients during the diagnostic work-up and during follow-up.
Extended national and international networks collecting information on diagnosis, management and
outcomes of patients with active or latent TB infections can be useful tools to help reaching the WHO
goal of ending global Tuberculosis epidemic by the year 2035 [1].
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FIGURE 2 Tuberculosis treatment front page.
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